Rational design of autotaxin inhibitors by structural evolution of endogenous modulators

Willem-Jan Keune, Frances Potjewyd, Tatjana Heidebrecht, Fernando Salgado-Polo, Simon J. F. Macdonald, Lakshman Chelvarajan, Ahmed Abdel Latif, Sony Soman, Andrew J. Morris, Allan J. B. Watson, Craig Jamieson, Anastassis Perrakis

Research output: Contribution to journalArticle

8 Citations (Scopus)
16 Downloads (Pure)

Abstract

Autotaxin produces the bioactive lipid lysophosphatidic acid (LPA), and is a drug target of considerable interest for numerous pathologies. We report the expedient, structure-guided evolution of weak physiological allosteric inhibitors (bile salts) into potent competitive Autotaxin inhibitors that do not interact with the catalytic site. Functional data confirms that our lead compound attenuates LPA mediated signalling in cells, and reduces LPA synthesis in vivo, providing a promising natural product derived scaffold for drug discovery.
Original languageEnglish
Pages (from-to)2006-2017
Number of pages12
JournalJournal of Medicinal Chemistry
Volume60
Issue number5
Early online date6 Feb 2017
DOIs
Publication statusPublished - 9 Mar 2017

Fingerprint

Drug Discovery
Biological Products
Bile Acids and Salts
Catalytic Domain
Pathology
Lipids
Pharmaceutical Preparations
lysophosphatidic acid
Lead

Keywords

  • lipid lysophosphatidic acid
  • autotaxin
  • allosteric inhibitors
  • scaffolds
  • drug discovery
  • catalytic site
  • cell signalling

Cite this

Keune, W-J., Potjewyd, F., Heidebrecht, T., Salgado-Polo, F., Macdonald, S. J. F., Chelvarajan, L., ... Perrakis, A. (2017). Rational design of autotaxin inhibitors by structural evolution of endogenous modulators. Journal of Medicinal Chemistry, 60(5), 2006-2017. https://doi.org/10.1021/acs.jmedchem.6b01743
Keune, Willem-Jan ; Potjewyd, Frances ; Heidebrecht, Tatjana ; Salgado-Polo, Fernando ; Macdonald, Simon J. F. ; Chelvarajan, Lakshman ; Abdel Latif, Ahmed ; Soman, Sony ; Morris, Andrew J. ; Watson, Allan J. B. ; Jamieson, Craig ; Perrakis, Anastassis. / Rational design of autotaxin inhibitors by structural evolution of endogenous modulators. In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 5. pp. 2006-2017.
@article{5f364dac47304ed0917086a25e29453c,
title = "Rational design of autotaxin inhibitors by structural evolution of endogenous modulators",
abstract = "Autotaxin produces the bioactive lipid lysophosphatidic acid (LPA), and is a drug target of considerable interest for numerous pathologies. We report the expedient, structure-guided evolution of weak physiological allosteric inhibitors (bile salts) into potent competitive Autotaxin inhibitors that do not interact with the catalytic site. Functional data confirms that our lead compound attenuates LPA mediated signalling in cells, and reduces LPA synthesis in vivo, providing a promising natural product derived scaffold for drug discovery.",
keywords = "lipid lysophosphatidic acid , autotaxin, allosteric inhibitors, scaffolds, drug discovery, catalytic site, cell signalling",
author = "Willem-Jan Keune and Frances Potjewyd and Tatjana Heidebrecht and Fernando Salgado-Polo and Macdonald, {Simon J. F.} and Lakshman Chelvarajan and {Abdel Latif}, Ahmed and Sony Soman and Morris, {Andrew J.} and Watson, {Allan J. B.} and Craig Jamieson and Anastassis Perrakis",
note = "This document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Medicinal Chemistry, copyright {\circledC} American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.6b01743",
year = "2017",
month = "3",
day = "9",
doi = "10.1021/acs.jmedchem.6b01743",
language = "English",
volume = "60",
pages = "2006--2017",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "5",

}

Keune, W-J, Potjewyd, F, Heidebrecht, T, Salgado-Polo, F, Macdonald, SJF, Chelvarajan, L, Abdel Latif, A, Soman, S, Morris, AJ, Watson, AJB, Jamieson, C & Perrakis, A 2017, 'Rational design of autotaxin inhibitors by structural evolution of endogenous modulators', Journal of Medicinal Chemistry, vol. 60, no. 5, pp. 2006-2017. https://doi.org/10.1021/acs.jmedchem.6b01743

Rational design of autotaxin inhibitors by structural evolution of endogenous modulators. / Keune, Willem-Jan; Potjewyd, Frances; Heidebrecht, Tatjana; Salgado-Polo, Fernando; Macdonald, Simon J. F.; Chelvarajan, Lakshman; Abdel Latif, Ahmed; Soman, Sony; Morris, Andrew J.; Watson, Allan J. B.; Jamieson, Craig; Perrakis, Anastassis.

In: Journal of Medicinal Chemistry, Vol. 60, No. 5, 09.03.2017, p. 2006-2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rational design of autotaxin inhibitors by structural evolution of endogenous modulators

AU - Keune, Willem-Jan

AU - Potjewyd, Frances

AU - Heidebrecht, Tatjana

AU - Salgado-Polo, Fernando

AU - Macdonald, Simon J. F.

AU - Chelvarajan, Lakshman

AU - Abdel Latif, Ahmed

AU - Soman, Sony

AU - Morris, Andrew J.

AU - Watson, Allan J. B.

AU - Jamieson, Craig

AU - Perrakis, Anastassis

N1 - This document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Medicinal Chemistry, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.6b01743

PY - 2017/3/9

Y1 - 2017/3/9

N2 - Autotaxin produces the bioactive lipid lysophosphatidic acid (LPA), and is a drug target of considerable interest for numerous pathologies. We report the expedient, structure-guided evolution of weak physiological allosteric inhibitors (bile salts) into potent competitive Autotaxin inhibitors that do not interact with the catalytic site. Functional data confirms that our lead compound attenuates LPA mediated signalling in cells, and reduces LPA synthesis in vivo, providing a promising natural product derived scaffold for drug discovery.

AB - Autotaxin produces the bioactive lipid lysophosphatidic acid (LPA), and is a drug target of considerable interest for numerous pathologies. We report the expedient, structure-guided evolution of weak physiological allosteric inhibitors (bile salts) into potent competitive Autotaxin inhibitors that do not interact with the catalytic site. Functional data confirms that our lead compound attenuates LPA mediated signalling in cells, and reduces LPA synthesis in vivo, providing a promising natural product derived scaffold for drug discovery.

KW - lipid lysophosphatidic acid

KW - autotaxin

KW - allosteric inhibitors

KW - scaffolds

KW - drug discovery

KW - catalytic site

KW - cell signalling

UR - http://pubs.acs.org/journal/jmcmar

U2 - 10.1021/acs.jmedchem.6b01743

DO - 10.1021/acs.jmedchem.6b01743

M3 - Article

VL - 60

SP - 2006

EP - 2017

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 5

ER -

Keune W-J, Potjewyd F, Heidebrecht T, Salgado-Polo F, Macdonald SJF, Chelvarajan L et al. Rational design of autotaxin inhibitors by structural evolution of endogenous modulators. Journal of Medicinal Chemistry. 2017 Mar 9;60(5):2006-2017. https://doi.org/10.1021/acs.jmedchem.6b01743